We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galapagos | EU:GLPG | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.64 | -2.66% | 23.40 | 23.40 | 23.46 | 24.04 | 23.40 | 24.00 | 98,719 | 16:40:00 |
By Ben Glickman
Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.
The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.
Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 04, 2024 16:29 ET (21:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Galapagos Chart |
1 Month Galapagos Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions